AOD-9604

How It Works

The biology, explained.

Growth hormone is much more than a hormone that makes children grow taller.

It also influences metabolism.

Among its many effects, growth hormone can affect how the body processes and stores fat.

But administering full-length growth hormone has consequences throughout the body.

It can affect IGF-1, glucose regulation, and other physiological systems.

Researchers wondered whether they could separate some of those effects.

A small piece of a much larger hormone

Human growth hormone contains 191 amino acids.

AOD-9604 contains just 16.

Its structure is based on the last 15 amino acids of mature human growth hormone, with an additional tyrosine at the beginning.

It also contains a disulfide bond connecting two cysteine residues.

That gives part of the peptide a loop-like structure.

The fat-metabolism hypothesis

Your body stores energy in fat cells, also called adipocytes.

Fat can be released from storage through a process called lipolysis.

During lipolysis, stored triglycerides are broken down into fatty acids and glycerol.

Researchers investigated whether AOD-9604 could influence this process.

Early experiments suggested that the peptide could increase certain fat-mobilization responses in animal systems.

Some studies also investigated its effects on the formation or accumulation of fat.

That generated excitement about its possible use in obesity.

Does it work like growth hormone?

Not exactly.

AOD-9604 is derived from the growth-hormone molecule, but it is not full-length growth hormone.

It was designed to investigate selected metabolic properties without reproducing the entire hormone's biological activity.

In controlled human studies, researchers did not observe significant increases in circulating IGF-1 with the tested AOD-9604 regimens.

That was scientifically encouraging.

But it didn't establish meaningful fat loss.

Does it work like semaglutide or tirzepatide?

No.

Semaglutide and tirzepatide act through incretin hormone receptors involved in appetite and metabolic regulation.

AOD-9604 was investigated through a different biological hypothesis involving growth-hormone-derived metabolic effects.

There is no convincing evidence that AOD-9604 produces the same appetite-regulating or weight-loss effects as approved GLP-1-based medications.

What about its actual receptor?

Here's a fascinating unresolved question.

Although AOD-9604 has shown metabolic activity in experimental systems, its complete clinically relevant signaling mechanism has not been established.

It would be misleading to assign it a single confirmed therapeutic receptor responsible for human fat loss.

Some mechanistic research has explored adrenergic signaling and metabolic pathways, but the biology remains incompletely characterized.

The cartilage connection

Cartilage is the smooth tissue that cushions the ends of bones inside joints.

Osteoarthritis involves changes in cartilage, bone, inflammation, and other joint structures.

Researchers have investigated whether AOD-9604 influences cartilage-related cells and experimental joint degeneration.

Animal studies have suggested possible effects on cartilage preservation or repair-related measurements.

That's interesting because cartilage research addresses a different clinical question from obesity.

But a promising animal joint experiment does not establish a treatment for human arthritis.

Go deeper: The science

AOD-9604 is a synthetic analog of the C-terminal region of human growth hormone.

Its sequence is Tyr–Leu–Arg–Ile–Val–Gln–Cys–Arg–Ser–Val–Glu–Gly–Ser–Cys–Gly–Phe.

The cysteines at positions 7 and 14 form an intramolecular disulfide bond.

The added N-terminal tyrosine distinguishes it from the unmodified hGH(177–191) fragment.

The molecule was investigated for metabolic activity while avoiding major activation of the broader GH–IGF-1 axis.

However, experimentally observed lipid-metabolism effects have not translated into convincing clinical weight-loss efficacy.

The Evidence

What do the studies actually show?

AOD-9604 has a more developed human research history than many peptides sold online.

That's important.

We don't have to rely exclusively on animal experiments or theoretical mechanisms.

We can examine what happened when researchers tested it in people.

Early animal research: The promising beginning

A study published in 2001 investigated AOD-9604 in obese Zucker rats.

These rats are used in research because they develop obesity-related metabolic changes.

The researchers administered AOD-9604 for 19 days and examined weight gain and fat metabolism.

The treated rats gained substantially less weight.

The researchers also found increased lipolytic activity in adipose tissue.

And unlike full-length growth hormone in that experimental comparison, AOD-9604 did not show the same adverse effect on insulin sensitivity.

That was a promising animal result—not proof that it would cause weight loss in humans.

The early human clinical program

Researchers went on to investigate AOD-9604 in several randomized, double-blind, placebo-controlled studies.

A 2013 publication summarized six human studies covering short-term intravenous administration, oral administration, and longer-term obesity treatment.

The studies examined safety, glucose regulation, IGF-1, adverse events, and weight-related outcomes.

The main scientific question was whether the compound could produce useful metabolic effects without unwanted growth-hormone-related changes.

The big test: OPTIONS

The pivotal obesity study enrolled 536 adults.

The FDA's review described 502 adults in the randomized, double-blind, placebo-controlled study population.

Participants had obesity and received either oral AOD-9604 or placebo alongside a supervised diet and exercise program.

Treatment continued for up to 24 weeks.

This is the critical finding.

The trial did not demonstrate a statistically significant reduction in body weight compared with placebo at 12 or 24 weeks.

The developer subsequently discontinued the obesity development program.

Why do people still talk about AOD-9604 for fat loss?

Because the early mechanism was appealing.

And some people see a biological rationale for promoting fat mobilization without stimulating the entire growth-hormone system.

But once a compound has undergone a substantial controlled clinical trial, those findings matter more than speculation.

It is possible for a substance to affect fat-related cellular processes without producing clinically meaningful weight loss.

Did it affect IGF-1 and blood sugar?

The human studies summarized in 2013 did not demonstrate significant IGF-1 elevations or major worsening of measured glucose regulation under the investigated conditions.

That supported part of the original hypothesis: the fragment could behave differently from full-length growth hormone.

However, those findings did not establish its safety for every administration route or duration.

And they did not rescue its disappointing obesity results.

A completely different research direction: Cartilage

In 2015, researchers published an experiment involving 32 rabbits with induced knee osteoarthritis.

The animals were divided into four treatment groups.

Researchers evaluated cartilage degeneration and lameness.

Both AOD-9604 and hyaluronic acid were associated with better outcomes than saline on selected measures.

But the most interesting result was the combination.

AOD-9604 plus hyaluronic acid outperformed either treatment alone on several cartilage-related and lameness measurements.

That raises an intriguing possibility.

Perhaps AOD-9604 deserves investigation for applications other than weight loss.

But this was a rabbit study involving administration directly into the joints.

It cannot establish that ordinary oral or subcutaneous AOD-9604 treats human osteoarthritis.

Does it rebuild cartilage in people?

We don't have convincing controlled human clinical evidence showing that it does.

The rabbit findings are a reason to investigate further, not proof of cartilage regeneration in patients.

What has AOD-9604 not demonstrated?

Despite considerable interest, it has not demonstrated:

• Clinically meaningful weight loss in its largest controlled obesity trial.
• Reliable loss of stubborn belly fat in humans.
• Improved body composition in rigorous trials of common research-vial use.
• Reduced visceral fat comparable to approved obesity therapies.
• Human cartilage regeneration.
• Effective treatment of osteoarthritis.
• Prevention of joint replacement.
• Longevity or anti-aging benefits.

The takeaway

AOD-9604 is a rare example of a popular peptide with a substantial human development program and a clear negative major efficacy result.

Its metabolic activity remains biologically interesting.

Its cartilage research opens another possible direction.

But a promising mechanism is not the same thing as a successful treatment.

Risks & Effects

What should people know?

AOD-9604 has more published human safety information than many investigational peptides.

That doesn't make every product or route of administration safe.

What did human studies find?

A 2013 publication summarized safety and tolerability findings from six controlled clinical studies.

Under the conditions studied, AOD-9604 generally showed a tolerability profile similar to placebo.

The researchers reported no major treatment-related changes in IGF-1 or glucose regulation.

That is useful information.

But it requires context.

Many participants received oral formulations.

Some earlier studies used short-term intravenous administration.

The research did not establish the safety of long-term subcutaneous use of products sold as research peptides.

Adverse effects observed in research

Reported symptoms in the clinical program included:

• Headache
• Gastrointestinal discomfort
• Diarrhea
• Flatulence
• Nausea
• Fatigue
• Dizziness

Many events occurred in placebo groups as well.

One oral-dose study recorded a serious diarrhea event considered possibly related to study treatment, while another serious event was assessed as unrelated.

So it would be inaccurate to say the human development program identified no adverse events whatsoever.

The FDA's later safety concerns

In its compounding assessments, the FDA identified potential concerns involving:

• Immunogenicity
• Peptide-related impurities
• Product characterization
• Insufficient safety information for proposed administration routes
• Serious adverse-event reports with uncertain causality

These concerns do not prove that every AOD-9604 product causes harm.

But they also cannot be dismissed simply because earlier oral trials appeared relatively well tolerated.

Oral versus injectable products

This distinction matters.

The largest weight-loss study used an oral formulation.

Many products promoted today involve subcutaneous injection.

Different routes can create different exposure patterns.

Results from oral trials cannot automatically establish either the effectiveness or long-term safety of injected research products.

The formulation problem

AOD-9604 contains a disulfide bond, and its behavior depends on formulation conditions.

In online discussions, people frequently report cloudiness, clumping, or gel-like material when attempting to dissolve certain research products.

These observations don't prove a particular chemical mechanism.

But they demonstrate why appearance alone isn't enough to establish correct formulation or suitability for injection.

A preparation with visible particles, persistent cloudiness, or unusual texture should not be assumed safe to administer.

Injection-site experiences

Some people describe burning, tenderness, swelling, redness, or itching following use of products labeled AOD-9604.

Others report no discomfort.

These accounts do not establish a reliable adverse-event frequency or identify the exact cause.

Possible factors may include formulation characteristics, impurities, and other variables.

Is it safe for athletes?

AOD-9604 is prohibited under the World Anti-Doping Agency's 2026 Prohibited List as a growth-hormone fragment.

That restriction applies independently of whether someone believes it improves athletic performance.

FDA status

AOD-9604 is not an FDA-approved medication for weight loss, cartilage repair, or another therapeutic indication.

Its appearance in compounding reviews does not establish approval, safety, or effectiveness.

Bottom line

AOD-9604 has meaningful human safety data from particular research settings.

But important gaps remain, especially for repeated subcutaneous use, product quality, and long-term exposure.

And its lack of demonstrated weight-loss efficacy is a separate issue from safety.

Real Experiences

What are people saying?

AOD-9604 attracts a slightly different crowd from many growth-hormone-related peptides.

People are often interested in one particular goal:

Losing stubborn body fat without using a conventional appetite-suppressing medication.

And the online experiences are sharply divided.

The good

Some people describe gradual changes in body composition, especially around the abdomen.

Others say they noticed better definition despite little change on the scale.

There are accounts of perceived progress after a frustrating weight-loss plateau.

One person described losing weight while using AOD-9604 alongside tirzepatide.

That sounds promising as a personal experience—but it doesn't establish which substance contributed to the result.

The not-so-good

Other users report little or no meaningful fat loss.

One person described using AOD-9604 for approximately two months, losing only a small amount of weight, and believing dietary changes and greater activity probably explained the result.

Another described using AOD-9604 alongside CJC-1295 and ipamorelin for months without the expected weight loss.

The frustrating

A recurring discussion is whether AOD-9604 works only for people who are already relatively lean and trying to lose a final amount of stubborn fat.

That's an interesting hypothesis.

But controlled evidence has not established a reliable subgroup of people who benefit in that way.

The painful part

Several users describe substantial burning or discomfort after using products labeled AOD-9604.

Some report redness, itching, or swelling.

Others describe no injection discomfort at all.

These differences may reflect many factors, including formulation, but the anecdotes alone cannot establish the explanation.

The strange chemistry discussions

Online communities frequently discuss products becoming cloudy, forming clumps, or appearing to gel.

Some users speculate about different diluents, acidity, and storage conditions.

These discussions are interesting from a formulation-science perspective.

But they are not validated pharmaceutical stability studies or reliable preparation instructions.

The complicated

People frequently use AOD-9604 alongside:

• Tirzepatide or semaglutide
• Other research peptides
• Calorie restriction
• Intermittent fasting
• Resistance training
• Increased cardio
• Changes in sleep or nutrition

Any of these could influence body weight or appearance.

That makes it difficult to determine what role, if any, AOD-9604 played.

So what should we believe?

The stories help explain why people remain interested.

But the large controlled obesity trial is a crucial counterweight.

Some individuals report positive changes, while the best available major efficacy study did not establish a reliable weight-loss advantage.

Sometimes the most interesting thing about a compound is why a promising theory didn't survive its big clinical test.

These summaries are based on genuine public discussions. Individual reports are unverified and do not establish clinical effectiveness, causation, or side-effect frequency.